Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

126.64
-1.2600-0.99%
Post-market: 126.650.0100+0.01%19:59 EDT
Volume:1.89M
Turnover:241.06M
Market Cap:18.56B
PE:12.52
High:129.78
Open:128.56
Low:125.97
Close:127.90
Loading ...

Biogen Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
06 Jun

Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment

Reuters
·
05 Jun

Entrada Therapeutics Appoints Dr. Maha Radhakrishnan to Board of Directors Amidst Clinical Advancements in Duchenne Therapies

Reuters
·
03 Jun

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
03 Jun

Biogen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
31 May

Biogen Inc. Stock Climbs 4.1%, Outperforms Competitors

Dow Jones
·
30 May

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-05-29

Reuters
·
29 May

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 May

Biogen’s Strategic Collaboration with City Therapeutics: A Buy Rating for Long-term Growth in RNAi Therapeutics

TIPRANKS
·
28 May

Biogen to Pay $46M in RNAi-Development Collaboration

Dow Jones
·
27 May

BRIEF-Biogen And City Therapeutics Announce Strategic Research Collaboration To Develop Select Novel Rnai-Based Therapies

Reuters
·
27 May

Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
22 May

Biogen Inc. Stock Rallies 3.1%, Outperforms Competitors

Dow Jones
·
20 May

U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma

Reuters
·
19 May

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
16 May

Market Chatter: Eisai, Biogen to Shift Some Lecanemab Ingredient Production to US Amid Tariff Concerns

MT Newswires Live
·
15 May

Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
15 May

Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset

TIPRANKS
·
14 May

Stoke Therapeutics Initiates Phase 3 Trial for Zorevunersen, Aiming to Launch First Disease-Modifying Treatment for Dravet Syndrome by Mid-2028

Reuters
·
13 May

Stoke Therapeutics Inc. Reports Q1 2025 Results: No Significant Changes in Sales, Revenue, or EPS Noted

Reuters
·
13 May